DEERFIELD, Ill.--(EON: Enhanced Online News)--Baxter International Inc. (NYSE: BAX), a leader in innovative technology
for medication delivery, today announced the U.S. Food and Drug
Administration (FDA) clearance of the Spectrum IQInfusion
System with Dose IQ Safety Software. The Spectrum IQ system
is the first-of-its-kind designed specifically for bi-directional
electronic medical records (EMR) integration with new exclusive features
to help ensure the correct medications and fluids are delivered to the
patient. The Spectrum IQ system also builds upon proven Spectrum
infusion pump technology and Baxter’s comprehensive approach to patient
safety to help make drug library compliance, protection for high-risk
infusions and auto-programming more consistently achievable for health
systems.

“EMR integration is an important step in making infusions safer, which
is why Baxter designed the Spectrum IQ system with features that
simplify EMR integration and help customers overcome EMR integration
adoption barriers,” said Scott Luce, general manager, U.S. Hospital
Products, Baxter. “These features set a new standard for medication
administration, helping enhance both patient safety and clinician
efficiency.”

The Spectrum IQ system provides the broadest range of
auto-programming workflows and feature sets as well as embedded
on-screen barcode technology that helps eliminate the need for a sticker
barcode and provides clinicians with scan prompts to help maintain or
increase auto-programming compliance and automatically document infusion
data into the EMR. In addition, the Spectrum IQ pump is the only
infusion pump to feature Line Check Notification technology* that
supports line management by providing a visual notification matching the
infusion pump and the medication being infused.

For the Spectrum IQ Infusion System, Baxter has partnered with
First Databank (FDB) to integrate FDB Infusion Knowledge™—an
evidence-based library of IV medications—into Dose IQ Safety
Software to help make delivery of infusions safer. FDB, a leading
provider of drug and medical device knowledge, supports healthcare
professionals in making informed decisions at the point of care,
intended to improve the quality of patient care.

The Spectrum IQ pump also includes leading features designed to
help drive the highest levels of drug library compliance in the
industry, such as automatically defaulting to the installed drug library
without requiring clinicians to take extra steps to utilize the safety
features and wireless drug library updates without interrupting clinical
workflow. Baxter’s Spectrum systems—including the Spectrum IQ system—are
the only infusion pumps with a built-in Dose/Rate Change Error
Prevention Feature, which helps clinicians protect high-risk infusions
during titrations, and helps allow pharmacists to customize dose change
limits for individual drugs.

Other key features designed to facilitate increased hospital efficiency
include:

Built-in DeviceVue Asset Tracking Application, which displays
pump status and location data on a PC, tablet or smartphone without
the need to interface with third-party real-time location systems**

Alarm and alert routing designed to help reduce “alert fatigue” among
nursing staff by sending alarm start and stop messages directly from
the pump bedside to secondary Alarms Management Systems, including
smartphones or work stations

*Line Check Notification technology only compatible with Cerner®
electronic health record (EHR) technology.**Pumps must have at
least 25% charge in order to continue providing data to DeviceVue.

Spectrum IQ Infusion System is Rx Only. For the safe and
proper use of this device, refer to the appropriate operator’s manuals.

About Baxter

Baxter International Inc. provides a broad portfolio of essential
healthcare products across its portfolio, including acute and chronic
dialysis therapies; sterile IV solutions; infusion systems and devices;
parenteral nutrition therapies; inhaled anesthetics; generic injectable
pharmaceuticals; and surgical hemostat and sealant products. The
company’s global footprint and the critical nature of its products and
services play a key role in expanding access to healthcare in emerging
and developed countries. Baxter’s employees worldwide are building upon
the company’s rich heritage of medical breakthroughs to advance the next
generation of healthcare innovations that enable patient care.

This release includes forward-looking statements concerning Baxter's
Spectrum IQ Infusion System and related performance data, including
anticipated benefits associated with its use. The statements are based
on assumptions about many important factors, including the following,
which could cause actual results to differ materially from those in the
forward-looking statements: satisfaction of regulatory and other
requirements; demand for and market acceptance of risks for new and
existing products; product development risks; product quality or patient
safety concerns; continuity, availability and pricing of acceptable raw
materials and component supply; inability to create additional
production capacity in a timely manner or the occurrence of other
manufacturing or supply difficulties (including as a result of a natural
disaster or otherwise); breaches or failures of the company’s
information technology systems, including by cyberattack; future actions
of regulatory bodies and other governmental authorities, including FDA
and foreign regulatory agencies; failures with respect to compliance
programs; future actions of third parties, including payers; U.S.
healthcare reform and other global austerity measures; pricing,
reimbursement, taxation and rebate policies of government agencies and
private payers; the impact of competitive products and pricing,
including disruptive technologies; accurate identification of and
execution on R&D opportunities and realization of anticipated benefits;
changes in law and regulations; and other risks identified in Baxter's
most recent filing on Form 10-K and other SEC filings, all of which are
available on Baxter's website. Baxter does not undertake to update its
forward-looking statements.

Baxter, Spectrum IQ, Dose IQ and DeviceVue are
trademarks of Baxter International Inc.

Cerner is a registered trademark of Cerner Corporation and/or its
subsidiaries.

COPENHAGEN--(EON: Enhanced Online News)--Baxter International Inc. (NYSE: BAX), a global innovator in renal care, announced the availability of two program updates for its SHARESOURCE remote patien... more »